Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01976884

Enrollment

Registered

2013-11-06

Start date

2011-06-30

Completion date

2013-01-31

Last updated

2013-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression, Sepsis

Keywords

sepsis, immunosuppression, PD-L1

Brief summary

Immunosuppression is the leading cause of death in septic patients. Neutrophils are classical components of innate immunology, but recent studies showed that neutrophils might display antigen presenting function and inhibit lymphocyte proliferation by expressing programmed cell death 1 ligand 1 (PD-L1). Whether neutrophils express PD-L1 and its role in immunosuppression during sepsis remain unclear.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients with severe sepsis * patients with sepsis after PCNL for infectious kidney stone * patients with pancreatic cancer * healthy volunteers

Exclusion criteria

* patients with immunodeficient diseases * patients who accept glucocorticoid or immunosuppressant * patients with an age older than 18 years * patients providing the informed consent

Design outcomes

Primary

Measure	Time frame	Description
PD-L1 level on neutrophils	within 24h after recruitment	PD-L1 level on neutrophils was compared between different populations.

Secondary

Measure	Time frame
28-day mortality	28 days after diagnosis of sepsis

Outcome results